Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Meclocycline Sulfosalicylate→

Meclocycline Sulfosalicylate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
73816-42-9
Molecular formula
C29H27ClN2O14S
Molecular weight
695 g/mol
Drug class
Tetracycline antibacterialtopical 30S ribosomal protein-synthesis inhibitor
Mechanism of action
A sulfosalicylate salt of meclocycline, a tetracycline antibiotic. It binds to the bacterial 30S ribosomal subunit and inhibits addition of amino acids to the growing peptide chain, producing bacteriostatic activity.
Indications / reported uses
  • Topical treatment of acne vulgaris with authorised meclocycline sulfosalicylate preparations; clinical trials have evaluated reductions in inflammatory and comedonal acne lesions.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/meclocycline-sulfosalicylate · https://pubmed.ncbi.nlm.nih.gov/6209900/ · https://pubmed.ncbi.nlm.nih.gov/6452987/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Meclocycline Sulfosalicylate Environmental Risk Assessment (ERA) (the Meclocycline Sulfosalicylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.